ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Alejandro Recio‐Boiles
Matched on ORCID iD 0000-0002-5423-3112; OpenAlex author ID A5018235125. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper
Papers 6
- Health Disparities in Presentation, Treatment, Genomic Testing, and Outcomes of Pancreatic Cancer in Hispanic and Non-Hispanic Patients. Last author DOI 10.1007/s40615-022-01486-1↗
- Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. First author DOI 10.1080/14656566.2022.2149322↗
- Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institu… Co-author DOI 10.21037/apc.2020.02.01↗
- Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1080/13543784.2019.1632289↗
- Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal a… Co-author DOI 10.21037/apc.2019.06.01↗
- JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident st… Co-author DOI 10.18632/oncotarget.7066↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hani M. Babiker · 4 shared papers, 2019–2022 · strength 0.47
- Paper Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. DOI 10.1080/14656566.2022.2149322↗
- Paper Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). DOI 10.1080/13543784.2019.1632289↗
- Paper Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the per… DOI 10.21037/apc.2020.02.01↗
- Ali McBride · 3 shared papers, 2019–2020 · strength 0.32
- Paper Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). DOI 10.1080/13543784.2019.1632289↗
- Paper Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the per… DOI 10.21037/apc.2020.02.01↗
- Paper Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in pati… DOI 10.21037/apc.2019.06.01↗
- Sreenivasa Rao Chandana · 2 shared papers, 2019–2022 · strength 0.27
- Daruka Mahadevan · 2 shared papers, 2019–2022 · strength 0.27
- Ritika Halder · 1 shared paper, 2023 · strength 0.24
- Mitesh J. Borad · 1 shared paper, 2022 · strength 0.15
- Muhammad Sardar · 1 shared paper, 2022 · strength 0.15
- Kabir Mody · 1 shared paper, 2022 · strength 0.15
- Aaron James Scott · 1 shared paper, 2020 · strength 0.11
- Jody V. Vykoukal · 1 shared paper, 2016 · strength 0.06
- Matthias Ilmer · 1 shared paper, 2016 · strength 0.06
- Eckhard Alt · 1 shared paper, 2016 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.